Etravirine
CAS: 269055-15-4
Ref. 3D-FA16346
| 1g | 426.00 € | ||
| 2g | 720.00 € | ||
| 5g | 1,123.00 € | ||
| 250mg | 162.00 € | ||
| 500mg | 238.00 € |
Estimated delivery in United States, on Friday 13 Dec 2024
Product Information
Name:
Etravirine
Synonyms:
- 4-[[6-Amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl -benzonitrileIntelenceEtravirineR 165335TMC 125
- 4-((6-Amino-5-Bromo-2-((4-Cyanophenyl)Amino)-4-Pyrimidinyl)Oxy)-3,5-Dimethyl-Benzonitrile
- 4-(6-Amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yloxy)-3,5-dimethylbenzonitrile
- 4-({6-Amino-5-Bromo-2-[(4-Cyanophenyl)Amino]Pyrimidin-4-Yl}Oxy)-3,5-Dimethylbenzonitrile
- 4-({6-Amino-5-brom-2-[(4-cyanphenyl)amino]pyrimidin-4-yl}oxy)-3,5-dimethylbenzolcarbonitril
- 4-[[6-Amino-5-Bromo-2-[(4-Cyanophenyl)Amino]-4-Pyrimidinyl]Oxy]-3,5�CDimethylbenzonitrile
- 4-[[6-Amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethylbenzonitrile
- 6-Amino-5-Bromo-4-(4-Cyano-2,6-Dimethylphenoxy)-2-(4-Cyanophenylamino)Pyrimidine
- Benzonitrile, 4-((6-amino-5-bromo-2-((4-cyanophenyl)amino)-4-pyrimidinyl)oxy)-3,5-dimethyl-
- Etravirine [INN]
- See more synonyms
- Etravirine [USAN:INN]
- Intelence
- R 165335
- R165335-Tmc125
- Tmc 125
- Tmc125
- Unii-0C50Hw4Fo1
Description:
Anti-viral; non-nucleoside reverse transcriptase inhibitor
Notice:
Our products are intended for lab use only. For any other use, please contact us.
Brand:
Biosynth
Long term storage:
Notes:
Chemical properties
Molecular weight:
435.28 g/mol
Formula:
C20H15BrN6O
Purity:
Min. 98 Area-%
Color/Form:
White Yellow Powder
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:
Technical inquiry about: 3D-FA16346 Etravirine
Please use instead the cart to request a quotation or an order
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
